SOCIETY: AASLD

Presentations:

ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS

ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

EFFECT OF EMPAGLIFLOZIN ON LIVER FAT IN METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITHOUT DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

PROJECTED PREVALENCE OF CIRRHOSIS AND OVERT HEPATIC ENCEPHALOPATHY IN THE UNITED STATES, 2021–2030

EVALUATING THE IMPACT OF CO-EXISTING INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A LARGE COHORT RETROSPECTIVE STUDY

Carla Brady

Duke University

Appearances